Business Description
Neuland Laboratories Ltd
ISIN : INE794A01010
Compare
Compare
Traded in other countries / regions
NEULANDLAB.India IPO Date
2008-10-13Description
Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.4 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 43.82 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 12.51 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.1 | |||||
| 3-Year EBITDA Growth Rate | 40.2 | |||||
| 3-Year EPS without NRI Growth Rate | 117.6 | |||||
| 3-Year FCF Growth Rate | 171.5 | |||||
| 3-Year Book Growth Rate | 11.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.42 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.66 | |||||
| 9-Day RSI | 61.67 | |||||
| 14-Day RSI | 61 | |||||
| 6-1 Month Momentum % | 67.23 | |||||
| 12-1 Month Momentum % | 217.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | |||||
| Quick Ratio | 1.33 | |||||
| Cash Ratio | 0.35 | |||||
| Days Inventory | 137.8 | |||||
| Days Sales Outstanding | 74.05 | |||||
| Days Payable | 75.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.13 | |||||
| Dividend Payout Ratio | 0.04 | |||||
| 3-Year Dividend Growth Rate | 16 | |||||
| Forward Dividend Yield % | 0.13 | |||||
| 5-Year Yield-on-Cost % | 0.13 | |||||
| Shareholder Yield % | 1.33 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.88 | |||||
| Operating Margin % | 27.94 | |||||
| Net Margin % | 20.43 | |||||
| FCF Margin % | 11.02 | |||||
| ROE % | 31.61 | |||||
| ROA % | 20.37 | |||||
| ROIC % | 24.85 | |||||
| ROC (Joel Greenblatt) % | 52.07 | |||||
| ROCE % | 37.33 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.15 | |||||
| PE Ratio without NRI | 29.15 | |||||
| Shiller PE Ratio | 149.77 | |||||
| Price-to-Owner-Earnings | 59.94 | |||||
| PEG Ratio | 0.78 | |||||
| PS Ratio | 5.95 | |||||
| PB Ratio | 8.16 | |||||
| Price-to-Tangible-Book | 11.4 | |||||
| Price-to-Free-Cash-Flow | 54.02 | |||||
| Price-to-Operating-Cash-Flow | 38.96 | |||||
| EV-to-EBIT | 22.44 | |||||
| EV-to-Forward-EBIT | 14.46 | |||||
| EV-to-EBITDA | 19.82 | |||||
| EV-to-Forward-EBITDA | 10.15 | |||||
| EV-to-Revenue | 6.21 | |||||
| EV-to-Forward-Revenue | 1.64 | |||||
| EV-to-FCF | 53.78 | |||||
| Price-to-Projected-FCF | 9.46 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.22 | |||||
| Price-to-Graham-Number | 4.3 | |||||
| Price-to-Net-Current-Asset-Value | 32.18 | |||||
| Earnings Yield (Greenblatt) % | 4.45 | |||||
| FCF Yield % | 1.77 | |||||
| Forward Rate of Return (Yacktman) % | 20.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neuland Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 15,521.119 | ||
| EPS (TTM) (₹) | 247.13 | ||
| Beta | 0.08 | ||
| Volatility % | 53.34 | ||
| 14-Day RSI | 61 | ||
| 14-Day ATR (₹) | 302.436139 | ||
| 20-Day SMA (₹) | 7067.6175 | ||
| 12-1 Month Momentum % | 217.71 | ||
| 52-Week Range (₹) | 2031.05 - 7790 | ||
| Shares Outstanding (Mil) | 12.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuland Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuland Laboratories Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neuland Laboratories Ltd Frequently Asked Questions
What is Neuland Laboratories Ltd(NSE:NEULANDLAB)'s stock price today?
The current price of NSE:NEULANDLAB is ₹7557.85. The 52 week high of NSE:NEULANDLAB is ₹7790.00 and 52 week low is ₹2031.05.
When is next earnings date of Neuland Laboratories Ltd(NSE:NEULANDLAB)?
The next earnings date of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 2024-05-10 Est..
Does Neuland Laboratories Ltd(NSE:NEULANDLAB) pay dividends? If so, how much?
The Dividend Yield %  of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 0.13% (As of Today), Highest Dividend Payout Ratio of Neuland Laboratories Ltd(NSE:NEULANDLAB) was 0.26. The lowest was 0.03. And the median was 0.05. The  Forward Dividend Yield % of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 0.13%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers